Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

Jan 1, 2023, 00:00 AM
10.1016/j.jval.2022.07.002
https://www.valueinhealthjournal.com/article/S1098-3015(22)02098-8/fulltext
Section Title : COMPARATIVE-EFFECTIVENESS RESEARCH/HTA
Section Order : 64
First Page : 64

Objectives

This study aimed to compare the relative efficacy of lorlatinib, an anaplastic lymphoma kinase–tyrosine kinase inhibitor, with chemotherapy, for patients with second-line or later advanced anaplastic lymphoma kinase–positive non–small cell lung cancer. The endpoints of interest were overall survival (OS) and progression-free survival (PFS).

Methods

Evidence for lorlatinib was informed by the single-arm phase I/II trial B7461001. A systematic literature review (SLR) was performed to identify OS and PFS data for chemotherapy. Unanchored matching-adjusted indirect comparisons (MAICs) between lorlatinib and chemotherapy (pemetrexed/docetaxel, platinum-based, or systemic therapy) were performed.

Results

The SLR identified 3 relevant studies reporting PFS. Lorlatinib was associated with a significant decrease in the hazard of progression versus the 2 types of chemotherapy assessed. For PFS, the MAIC of lorlatinib versus the combined treatment arm of docetaxel or pemetrexed resulted in an adjusted hazard ratio (HR) of 0.22 (95% confidence interval [CI] 0.15-0.31). When lorlatinib was compared with platinum-based chemotherapy through an MAIC, the adjusted HR for PFS was 0.40 (95% CI 0.29-0.55). An exploratory comparison was performed for OS with evidence for systemic therapy (assumed equivalent to chemotherapy) not identified in the SLR. Lorlatinib provided a significant decrease in hazard of death (OS) versus systemic therapy, with HRs ranging from 0.12 (95% CI 0.05-0.27) to 0.43 (95% CI 0.27-0.60).

Conclusions

Lorlatinib demonstrated a significant improvement in PFS compared with chemotherapy, although limitations in the analyses were identified. The evidence informing OS comparisons was highly limited but suggested benefit of lorlatinib compared with systemic therapy.

https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02098-8&doi=10.1016/j.jval.2022.07.002
HEOR Topics :
  • Clinical Outcomes
  • Comparative Effectiveness or Efficacy
  • Literature Review & Synthesis
  • Meta-Analysis & Indirect Comparisons
  • Oncology
  • Specific Diseases & Conditions
  • Study Approaches
Tags :
  • ALK-positive
  • chemotherapy
  • indirect treatment comparison
  • lorlatinib
  • non–small cell lung cancer
Regions :
  • Global